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Abstract
Background: Scientists engaged in global health research are increasingly faced with barriers to access and use of
human tissues from the developing world communities where much of their research is targeted. In part, the
problem can be traced to distrust of researchers from affluent countries, given the history of ‘scientific-imperialism’
and ‘biocolonialism’ reflected in past well publicized cases of exploitation of research participants from low to
middle income countries.
Discussion: To a considerable extent, the failure to adequately engage host communities, the opacity of informed
consent, and the lack of fair benefit-sharing have played a significant role in eroding trust. These ethical
considerations are central to biomedical research in low to middle income countries and failure to attend to them
can inadvertently contribute to exploitation and erode trust. A ‘tissue trust’ may be a plausible means for enabling
access to human tissues for research in a manner that is responsive to the ethical challenges considered.
Summary: Preventing exploitation and restoring trust while simultaneously promoting global health research calls
for innovative approaches to human tissues research. A tissue trust can reduce the risk of exploitation and promote
host capacity as a key benefit.
Background
Access and use of human tissues from the developing
world is a significant challenge for scientists engaged in
global health research. Given the troubled history of
‘scientific-imperialism’ and ‘biocolonialism’ in cases of
exploitation in research involving vulnerable populations
[1-6], many communities and governments in low-to-
middle income countries (LMICs) are understandably
reluctant to trust foreign researchers and permit access
to human tissues. The refusal of the Indonesian govern-
ment to share its tissue samples of the H5N1 virus with
the international community is perhaps the most acute
recent example [7]. The biomedical literature is filled
with numerous examples of researchers who were wel-
comed into a community, conducted their research, and
then left without returning any meaningful benefit to
the studied population. In some cases, researchers
appropriated human tissues from the host community
without obtaining proper informed consent. Consider:
“[B]lood samples were extracted from some members
of the Hagahai, a small group of hunter-gatherers living
in an inaccessible mountain range in Papua New Guinea.
The researcher involved told the group that she wanted
to see a ‘binitang’ – an insect – in their blood. Analysis of
these blood samples revealed existence of antibodies to a
variant of the HTLV-I leukaemia virus. This was used to
produce an immortal cell line, which was the basis for a
patent application...” [3]
“[T]he 400 blood samples from members of Arizona’s
Havasupai Tribe, which are at the centre of a lawsuit
against Arizona University, and which allegedly formed
the basis for no less than 23 scholarly papers, articles
and dissertations”. The lawsuit claims the Tribe’s genetic
information was used for research purposes not contem-
plated in the consent process [4].
“[A]s the Karitiana Indians remember it, the first
researchers to draw their blood came here in the late
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1970s...In 1996, another team visited, promising medi-
cine if the Karitiana would just give more blood, so they
dutifully lined up again. But that promise was never
fulfilled...” [2]
Central to biomedical research in low to middle
income countries (LMICs) are three inter-related chal-
lenges: informed consent, community engagement, and
benefit sharing. Failure to adequately address these chal-
lenges can lead to exploitation and the erosion of trust.
While these challenges have been addressed individually
in research guidelines, specific difficulties encountered
by researchers with respect to access and use of human
tissue samples in LMICs, and tighter country-level
restrictions in this regard [8,9] suggest a more holistic
solution is needed. In particular, there is a need to
develop approaches to human tissues research in LMICs
that are more responsive to exploitation, engaging parti-
cipants as legitimate stakeholders and not only as sub-
jects of research.
In this article, we briefly examine these three chal-
lenges and present a proposal for a tissue trust, a means
to address the challenges and the issue of exploitation
with respect to access and use of human tissues for
research in developing countries.
Discussion
Three Inter-related Ethical challenges: Informed Consent,
Community Engagement, Benefit Sharing
Informed consent
Informed consent remains one of the most vexing chal-
lenges for research involving participants from LMICs
[10]. Questions arise about the validity of consent –
whether participants were coerced, whether they under-
stood the risks and benefits of the research, whether
they were fully informed about how their data and tis-
sues would be used, and whether the consent process
was culturally appropriate. Autogen, the Australian
company that was refused a proposal to collect tissue
samples from Tongans to study diabetes, serves as an
example of where the informed consent process was
deemed culturally inappropriate because community
values were overlooked by favoring an individualistic
approach [5,11].
Another example of the challenge of informed consent
is where tissues are subjected to uses or handling that
were not made explicit, but could be implied or inferred
from what is agreed upon in the consent. For example,
a participant agrees that their blood sample will be sub-
jected to analysis involving a particular method, but the
method is locally unavailable and it is necessary to
export the tissue out of the country –something which
the participant objects to, but has not explicitly articu-
lated. This highlights a key problem of informed con-
sent: that it is opaque and can be significantly limited in
practice [10]. It also highlights the importance of enga-
ging with the host community so that proper determina-
tions regarding values and preferences can be made, and
proper disclosure with respect to handling and uses of
tissues is accounted for, including the possibility of
unknown future research uses and commercialization.
Community engagement
Community engagement is recognized by international
research ethics guidelines which have declared it an
ethical requirement for research involving human par-
ticipants [12,13]. In the context of research involving
human tissues from LMICs, community engagement is
essential for gaining an understanding of the special
significance tissues may hold, and thus for negotiating
culturally acceptable means of access and use. More-
over, community engagement is crucial for discovering
preferences with respect to the informed consent pro-
cess and understanding what constitutes fair distribu-
tion of research benefits from the perspective of
participants [1].
The failure to effectively engage communities can be
seen as a discounting of their values. As a result, partici-
pants may come to view research as the imposition of a
foreign agenda, eventually rejecting it. “Trials in devel-
oping countries have been halted or suspended for a
variety of reasons including lack of consensus on ethical
issues, lack of appropriate care and treatment of partici-
pants, and lack of adequate community consultation
[14]“. The tenofovir trials are a stark example of where
community engagement was seen to have failed.
Benefit-sharing
Benefit-sharing initially emerged as a mechanism to
restore equilibrium to the asymmetry between
researcher and participant when it became increasingly
visible that bioscience researchers, companies and
universities were accruing profits as a result of research
[15]. ‘Giving something back’ to participants is intended
to mitigate exploitation, and benefit-sharing is now gen-
erally considered a specific principle of research govern-
ance consistent with social justice. In developing world
contexts, benefit-sharing is considered a moral impera-
tive given the acute risk for exploitation of the poor and
sick and the desperate lack of resources.
In the past, the benefits for research participants in
LMICs have not been adequately or justly realized.
Some benefit-sharing agreements have been clearly inap-
propriate, e.g. DNA in exchange for toothbrushes [11];
while other agreements have aimed to be fair and equi-
table and still judged to be lacking from the perspective
of the community, e.g. Autogen and the Tongan people
[1]. The 2002 Bonn Guidelines offer a list of possible
benefits, both monetary (e.g. access fees, up front pay-
ment, joint ownership of relevant IP rights) and non-
monetary (sharing of research and development results,
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collaboration, development programs to build local
capacity) [16], but questions of what counts as an
appropriate return for the research context, or who is
the ultimate beneficiary, still need to be negotiated
between researcher and participant communities.
Empirical research in Africa has shown, that among
other reasons, lack of study benefits is a deterrent to
participation in research [17].
A Tissue Trust
In response to these ethical challenges, we propose a
‘tissue trust’ as a means of facilitating research involving
human tissues. By reducing exploitation through the
ratcheting up of local scientific capacity, the tissue trust
is responsive to the ethical challenges outlined above.
First, enabling tissue donors and community members
to participate in research governance ensures that the
consent of donors for access and use of tissues is
respected and reflective of community expectations. Sec-
ond, a well devised community engagement process that
must necessarily precede any attempts to implement a
tissue trust will account for the values and needs of the
host community and provide guidance for the govern-
ance of the trust. Lastly, a tissue trust is capable of
returning long term benefits to the source community
that extend beyond the fruits of research itself, such as
the improvement of healthcare facilities and the training
of local personnel which contributes to development.
The tissue trust is intended to serve the interests of
the common good and not just those that make contri-
butions. Thorsteinsdóttir et al have argued that in prin-
ciple genomics is a global public good, and what is
limiting this in practice is access goods [18] - this would
be provided by a tissue trust. This notion of the public
good finds support in the view that the fruits of genetic
research should be shared by all of humanity, as
espoused by the Human Genome Organisation (HUGO)
[19]. As well, the view of tissue resources as a common
good is preferable to conceptualizing tissues as a pro-
prietary good, which can elicit conflicts of ownership
and risk of commodification.
The idea of a tissue trust for managing tissue collec-
tions assembled for research is inspired by Winickoff
and Winickoff’s proposal for a charitable trust model for
genomic biobanks. In the Winickoffs’ model, tissues are
held in trust for the donors by a trustee who oversees
uses in accordance with the wishes of the beneficiaries
of the trust; in this case the general public [20]. The tis-
sue trust shares with the charitable trust common fea-
tures, namely having an independent third party
administer the trust on behalf of contributors for the
benefit of the wider community. The novel and distinc-
tive feature of the tissue trust is that it is specifically sui-
ted for the developing world context.
Mission and vision
The aim of the tissue trust is to build scientific capacity
in the developing world, to facilitate local research and
reduce exploitation by eliminating the need for exporta-
tion of tissues. To this end, the trust is designed with
mechanisms for promoting host capacity: it requires jus-
tification for the exportation of tissues and exacts a fee
from users submitting such requests. Over time, these
fees accumulate and are used for local investment in
scientific infrastructure, which returns benefits to the
host community over a sustained period of time that are
more fruitful than short-lived upfront payments to
donors or back-end payments contingent on successful
patents or commercialization. As local scientific capacity
builds up, the need to export tissues from the region is
gradually reduced and eventually eliminated. This gra-
dual ‘ratcheting up’ in capacity is consistent with the
vision of international research ethics Benatar and
Singer proposed almost a decade ago, aiming for the
improvement of standards rather than the setting of
unrealistic goals [21].
Governance
Governance of the trust is through a board of trustees
that acts as a fiduciary on behalf of the source commu-
nity, ensuring their interests are protected. The advan-
tage of having a fiduciary administer the trust is that it
minimizes the conflict of ownership which can arise
between tissue donors and the repositories they contri-
bute to. With a trust, no ownership rights are relin-
quished; rather ownership interests are transferred to
the trustee to manage according to the donor’s wishes.
The wishes of the source community are made explicit
through an effective community engagement process,
which naturally must precede the structuring of the tis-
sue trust. Access and use of tissues can remain consis-
tent with the expectations of the donors through their
participation in the governance of the trust; for example,
through membership on the board, the research ethics
committee (REC) or a donor committee with veto
power over particular projects [20]. The key element is
to engage the community upfront and sustain that
engagement through meaningful participation and buy-
in into the trust.
Organizational structure
The tissue trust is a model that can be applied on a pro-
ject, institutional, national, or regional basis. The trust is
structured as an independent non-profit entity with its
own board of trustees comprised of stakeholders that
include at least one elected member from the donor
community.
An obvious location for the physical infrastructure of
a tissue trust is at an institution with some infrastruc-
ture already in place, such as a hospital. The Winickoffs
outline three advantages for selecting an established
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medical institution: the unique relationships these insti-
tutions have with tissue and blood donors; the means to
attract public and private funds; and the capacity to
install good governance structures that can motivate
potential tissue donors [20]. Concerns regarding the
dominance of the host institution in managing the tissue
resource are eliminated by having a separate non-profit
organizational structure and governance that spans the
interests of relevant stakeholders. A data steward facili-
tates access and distribution of the tissues in accordance
with direction from the board of trustees. Additionally,
the trust has its own REC to review the scientific and
ethical merits of projects proposing access.
Business models and funding
Donors contribute tissues, while users proposing to
export tissues contribute funds. According to the
Winickoffs, biobanks can attract investment when public
benefit, rather than profit, serves as the organizing prin-
ciple [20]. To this extent, initial funding for infrastruc-
ture for the tissue trust could be supplied by institutions
having a stake in public health, e.g. health departments,
national research funding bodies, and foundations.
Thereafter, access fees for tissues requiring exportation
would be applied and those levies used for scientific
capacity building. This raises the question of whether
sufficient funds will be generated through such a
mechanism to make a meaningful contribution to build-
ing capacity; at present this is unknown. A limitation of
the tissue trust is that it is a concept that remains to be
tested. Moreover, further empirical research is required
to ascertain the volume of tissues exported from the
developing world, but there is some indication that this
may be substantial. It has been reported that Uganda is
losing millions of dollars due to exportation of human
biological samples [1].
As well, partnerships with the private sector should
not be discounted as a source of funding. In their
account of the charitable trust, the Winickoffs urge trus-
tees to apply funding models that seek research partner-
ships instead of tissue buyers. They offer the example of
one non-profit tissue bank that has successfully imple-
mented a partnership with the private sector:
“PXE international –a rare-disease group that has
established a nonprofit blood and tissue bank –has
generated funding by negotiating intellectual-
property arrangements with commercial researchers.
“[20]
As a concept, the tissue trust may be seen as an ideal
model. However, the underlying principles of promoting
southern governance and increasing research capacity in
LMICs are broadly applicable to projects in the
developing world, and can be adopted even where for-
mal structural organization or business models are
lacking.
Summary
To facilitate the use of human tissues for global health
research it is important to understand the ethical chal-
lenges that presently stand in the way of access. In the
past, informed consent has not always been properly
obtained, communities were not sufficiently engaged,
and meaningful benefits were not returned to the source
community. These practices have contributed to the
exploitation of participants and served to undermine
trust in research. To respond to concerns of exploitation
that can arise in the access and use of human tissues
from the developing world, we propose a tissue trust.
The trust is a fund to which contributions are held and
used for the development of scientific infrastructure in
the developing world. In effect, the trust becomes an
investment tool used to build up local capacity, so that
eventually research may be conducted locally and expor-
tation of tissues can be reduced.
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